Nintedanib Reddy (Nintedanib)

Nintedanib is a tyrosine kinase inhibitor used to treat fibrotic lung diseases and certain cancers.

• Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression.
• Systemic sclerosis‑associated interstitial lung disease: improves forced vital capacity and stabilizes respiratory status.
• Non‑small cell lung cancer (in combination therapy): enhances overall treatment efficacy when combined with chemotherapy.

• Nintedanib blocks the intracellular kinase activity of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR 1‑3), fibroblast growth factor receptors (FGFR 1‑3) and platelet‑derived growth factor receptors (PDGFR α/β). By inhibiting these pathways, it reduces endothelial cell proliferation, fibroblast activation and angiogenesis, thereby limiting the formation of fibrotic tissue and tumor‑related vascular growth.

Nintedanib may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

• Diarrhea: frequent loose stools that may be mild to moderate.
• Nausea and vomiting: gastrointestinal discomfort often occurring early in therapy.
• Decreased appetite: reduced desire to eat leading to possible weight loss.
• Abdominal pain: intermittent stomach discomfort.
• Elevated liver enzymes: mild increases in ALT/AST observed in routine monitoring.

Serious or Rare Side Effects

• Hepatic failure: severe liver injury requiring discontinuation.
• Bleeding events: gastrointestinal or other hemorrhage, especially with anticoagulants.
• Arterial thromboembolism: risk of heart attack or stroke.
• Perforations of the gastrointestinal tract: rare but potentially life‑threatening.
• Severe infections: opportunistic infections in immunocompromised patients.

Before initiating Nintedanib, clinicians should consider several safety measures and monitoring requirements.

• Liver function monitoring: assess baseline ALT/AST and repeat regularly during therapy.
• Bleeding risk assessment: evaluate concomitant anticoagulant or antiplatelet use.
• Cardiovascular evaluation: monitor for signs of arterial thrombotic events.
• Gastrointestinal management: advise patients on hydration and antidiarrheal measures.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks.
• Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Nintedanib can interact with other medicines, requiring dose adjustments or avoidance.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure.
• Anticoagulants (warfarin, direct oral anticoagulants): heightened risk of bleeding.
• Other anti‑angiogenic agents (bevacizumab, sunitinib): additive toxicity to vascular endothelium.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise plasma levels.
• P‑glycoprotein inhibitors (e.g., verapamil): can affect drug transport.
• Non‑steroidal anti‑inflammatory drugs: increase gastrointestinal adverse events.
• Diuretics: risk of dehydration may exacerbate renal effects.